Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07022483 · ClinicalTrials.gov registry record · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
A Phase 3 study of Endometrial Cancer, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 710
- Enrollment target
- 20
- Study locations
NCT07022483 is a Phase 3 study of Endometrial Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 710 participants, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT07022483, a Phase 3 study of Endometrial Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 710 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.
Conditions Studied
Interventions
- DRUG Chemotherapy
- DRUG Trastuzumab Deruxtecan
Study Locations (20)
Other
- Beijing Cancer Hospital - Beijing
- The First Hospital of Jilin University - Changchun
- West China Second University Hospital, Sichuan University - Chengdu
- Obstetrics and Gynecology Hospital Affiliated to Zhejiang University School of Medicine - Hangzhou
- Zhejiang Cancer Hospital - Hangzhou
- Cancer Hospital of Shandong First Medical University - Jinan
- Linyi Cancer Hospital - Linyi
- Jiangxi Maternal and Child Health Hospital - Nanchang
- Guangxi Medical University Affiliated Tumor Hospital - Nanning
- Shanghai First Maternity and Infant HospitalShanghai First Maternity and Infant Hospital - Shanghai
- Shanghai Tenth People's Hospital - Shanghai
- Tianjin Medical University Cancer Institute & Hospital - Tianjin
- The First Affiliated Hospital of Wenzhou Medical University - Wenzhou
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology - Wuhan
- Union Hospital Tongji Medical College Huazhong University of Science and Technology - Wuhan
- Yantai Yuhuangding Hospital - Yantai
- Hyogo Cancer Center - Akashi-shi
Florida
- Mount Sinai Medical Center - Miami Beach
Louisiana
- Trials365 LLC - Shreveport
South Dakota
- Avera Medical Group Gynecologic Oncology Sioux Falls - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2032-03-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07022483
The ClinicalTrials.gov registry entry for NCT07022483 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 710 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (37% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy is the first listed.
NCT07022483 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT07022483 about?
NCT07022483 is a clinical study titled "Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer". This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.
What is the current status of trial NCT07022483?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 710 participants. The study started on 2025-09-30. Estimated completion is 2032-03-23.
What conditions does trial NCT07022483 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT07022483?
The interventions under investigation include: Chemotherapy (DRUG), Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT07022483?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07022483 being conducted?
This trial has 20 study locations across Florida, Louisiana, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RECRUITING · Phase 3
-
Vaginal Cuff Brachytherapy Fractionation Study
RECRUITING · Phase 3
-
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RECRUITING · Phase 3
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RECRUITING · Phase 3
-
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
RECRUITING · Phase 3
-
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.